Cargando…
Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome
Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310221/ https://www.ncbi.nlm.nih.gov/pubmed/35862263 http://dx.doi.org/10.1177/10760296221108967 |
_version_ | 1784753341631299584 |
---|---|
author | Ji, Ying Wang, Yan-Li Xu, Fang Jia, Xi-Bei Mu, Su-Hong Lyu, Hui-Yan Yuan, Xue-Ying Na, Shi-Ping Bao, Yu-Shi |
author_facet | Ji, Ying Wang, Yan-Li Xu, Fang Jia, Xi-Bei Mu, Su-Hong Lyu, Hui-Yan Yuan, Xue-Ying Na, Shi-Ping Bao, Yu-Shi |
author_sort | Ji, Ying |
collection | PubMed |
description | Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in inflammatory processes. Hypercoagulability is defined as the tendency to develop thrombosis according to fibrinogen and/or D dimer levels. Nephrotic syndrome is also considered to be a hypercoagulable state. The aim of this study is to investigate the association of soluble PDPN/CLEC-2 with hypercoagulability in nephrotic syndrome. Thirty-five patients with nephrotic syndrome and twenty-seven healthy volunteers were enrolled. PDPN, CLEC-2 and GPVI concentrations were tested by enzyme-linked immunosorbent assay (ELISA). Patients with nephrotic syndrome showed higher serum levels of PDPN and GPVI in comparison to healthy controls (P < .001, P = .001). PDPN levels in patients with nephrotic syndrome were significantly correlated with GPVI (r = 0.311; P = .025), hypoalbuminemia (r = −0.735; P < .001), hypercholesterolemia (r = 0.665; P < .001), hypertriglyceridemia (r = 0.618; P < .001), fibrinogen (r = 0.606; P < .001) and D-dimer (r = 0.524; P < .001). Area under the curve (AUC) for the prediction of hypercoagulability in nephrotic syndrome using PDPN was 0.886 (95% CI 0.804-0.967, P < .001). Cut-off value for the risk probability was 5.88 ng/ml. The sensitivity of PDPN in predicting hypercoagulability was 0.806, and the specificity was 0.846. When serum PDPN was >5.88 ng/ml, the risk of hypercoagulability was significantly increased in nephrotic syndrome (OR = 22.79, 95% CI 5.92-87.69, P < .001). In conclusion, soluble PDPN levels were correlated with hypercoagulability in nephrotic syndrome. PDPN has the better predictive value of hypercoagulability in nephrotic syndrome as well as was a reliable indicator of hypercoagulable state. |
format | Online Article Text |
id | pubmed-9310221 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-93102212022-07-26 Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome Ji, Ying Wang, Yan-Li Xu, Fang Jia, Xi-Bei Mu, Su-Hong Lyu, Hui-Yan Yuan, Xue-Ying Na, Shi-Ping Bao, Yu-Shi Clin Appl Thromb Hemost Original Manuscript Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in inflammatory processes. Hypercoagulability is defined as the tendency to develop thrombosis according to fibrinogen and/or D dimer levels. Nephrotic syndrome is also considered to be a hypercoagulable state. The aim of this study is to investigate the association of soluble PDPN/CLEC-2 with hypercoagulability in nephrotic syndrome. Thirty-five patients with nephrotic syndrome and twenty-seven healthy volunteers were enrolled. PDPN, CLEC-2 and GPVI concentrations were tested by enzyme-linked immunosorbent assay (ELISA). Patients with nephrotic syndrome showed higher serum levels of PDPN and GPVI in comparison to healthy controls (P < .001, P = .001). PDPN levels in patients with nephrotic syndrome were significantly correlated with GPVI (r = 0.311; P = .025), hypoalbuminemia (r = −0.735; P < .001), hypercholesterolemia (r = 0.665; P < .001), hypertriglyceridemia (r = 0.618; P < .001), fibrinogen (r = 0.606; P < .001) and D-dimer (r = 0.524; P < .001). Area under the curve (AUC) for the prediction of hypercoagulability in nephrotic syndrome using PDPN was 0.886 (95% CI 0.804-0.967, P < .001). Cut-off value for the risk probability was 5.88 ng/ml. The sensitivity of PDPN in predicting hypercoagulability was 0.806, and the specificity was 0.846. When serum PDPN was >5.88 ng/ml, the risk of hypercoagulability was significantly increased in nephrotic syndrome (OR = 22.79, 95% CI 5.92-87.69, P < .001). In conclusion, soluble PDPN levels were correlated with hypercoagulability in nephrotic syndrome. PDPN has the better predictive value of hypercoagulability in nephrotic syndrome as well as was a reliable indicator of hypercoagulable state. SAGE Publications 2022-07-21 /pmc/articles/PMC9310221/ /pubmed/35862263 http://dx.doi.org/10.1177/10760296221108967 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Manuscript Ji, Ying Wang, Yan-Li Xu, Fang Jia, Xi-Bei Mu, Su-Hong Lyu, Hui-Yan Yuan, Xue-Ying Na, Shi-Ping Bao, Yu-Shi Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome |
title | Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome |
title_full | Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome |
title_fullStr | Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome |
title_full_unstemmed | Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome |
title_short | Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome |
title_sort | elevated soluble podoplanin associates with hypercoagulability in patients with nephrotic syndrome |
topic | Original Manuscript |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310221/ https://www.ncbi.nlm.nih.gov/pubmed/35862263 http://dx.doi.org/10.1177/10760296221108967 |
work_keys_str_mv | AT jiying elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome AT wangyanli elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome AT xufang elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome AT jiaxibei elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome AT musuhong elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome AT lyuhuiyan elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome AT yuanxueying elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome AT nashiping elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome AT baoyushi elevatedsolublepodoplaninassociateswithhypercoagulabilityinpatientswithnephroticsyndrome |